BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moqueet N, Cooper C, Gill J, Hull M, Platt RW, Klein MB; Canadian Co-infection Cohort. Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. J Infect Dis 2016;214:80-6. [PMID: 26984148 DOI: 10.1093/infdis/jiw088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Moqueet N, Kanagaratham C, Gill MJ, Hull M, Walmsley S, Radzioch D, Saeed S, Platt RW, Klein MB; Canadian Co-infection Cohort Study (CTN 222). A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. PLoS One 2017;12:e0176282. [PMID: 28467457 DOI: 10.1371/journal.pone.0176282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
3 Jeyarajan AJ, Chung RT. Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure? J Infect Dis 2020;222:S802-13. [PMID: 33245355 DOI: 10.1093/infdis/jiaa279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Frias M, Rivero-Juárez A, López-López P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. Pharmacogenomics 2018;19:979-95. [PMID: 29992850 DOI: 10.2217/pgs-2018-0046] [Reference Citation Analysis]
5 Eslam M, George J. Targeting IFN-λ: therapeutic implications. Expert Opinion on Therapeutic Targets 2016;20:1425-32. [DOI: 10.1080/14728222.2016.1241242] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
6 Huang CM, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tsai MC, Tseng PL, Lin MT, Wu CK, Hu TH, Cho CL, Yen YH. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS One 2017;12:e0182204. [PMID: 28797039 DOI: 10.1371/journal.pone.0182204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Rauff B, Amar A, Chudhary SA, Mahmood S, Tayyab GUN, Hanif R. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population. Arch Virol 2021;166:1047-56. [PMID: 33528661 DOI: 10.1007/s00705-020-04901-2] [Reference Citation Analysis]
8 Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 2017;33:120-7. [PMID: 28234770 DOI: 10.1097/MOG.0000000000000347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]